Authors

This educational activity has been developed by the Melanoma Research Foundation (MRF) and Mechanisms in Medicine Inc., with the assistance of the following Expert Faculty, who are experts in melanoma:

Dr. Jeffrey S. Weber, MD, PhD
Deputy Director
Laura and Isaac Perlmutter Cancer Center
Professor of Medicine
NYU Langone Medical Center
New York, NY
USA

Disclosure of Conflicts of Interest: Dr. Jeffrey S. Weber – Nothing to disclose.

Dr. Laura K. Ferris, MD, PhD
Professor and Chair
Department of Dermatology
University of North Carolina
Chapel Hill, NC
USA

Disclosure of Conflicts of Interest: Dr. Laura K. Ferris – Consulting fees received from DermTech. Research funding received from Castle Biosciences.

Dr. Rekha Chaudhary, MD
Professor of Medicine, Division of Hematology and Oncology
University of Cincinnati
Cincinnati, OH
USA

Disclosure of Conflicts of Interest: Dr. Rekha Chaudhary – Speakers bureau for Bristol Myers Squibb, Merck, and Castle Biosciences.

Dr. Michael B. Atkins, MD
Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center
William M. Scholl Professor and Vice-Chair Department of Oncology and
Professor of Medicine, Georgetown University Medical Center
Washington, DC
USA

Disclosure of Conflicts of Interest: Dr. Michael B. Atkins – Scientific Advisory Board: Werewolf and Pyxis Oncology; Consultant/Advisory Boards: Bristol Myers Squibb, Merck, Novartis, Eisai, Aveo, Pfizer, Werewolf, Fathom, Pyxis Oncology, PACT, Elpis, X4Pharma, ValoHealth, ScholarRock, Surface, Takeda, Roche, SAB Bio, Exelixis, Iovance, COTA, Idera, Agenus, Asher Bio, AstraZeneca, SeaGen, Sanofi, OncoRena, Pliant Therapeutics, GSK.

Dr. Sapna P. Patel, MD
Melanoma Medical Oncologist
Chair, SWOG Cancer Research Network
Houston, TX
USA

Disclosure of Conflicts of Interest: Dr. Sapna P. Patel – Research funding received from: Bristol Myers Squibb, Foghorn Therapeutics, IDEAYA Biosciences, InxMed; Lyvgen Biopharma, Novartis, Provectus Biopharmaceuticals, Seagen, Syntrix Pharmaceuticals, TriSalus Life Sciences; Consulting fees received from: Bristol Myers Squibb, Cardinal Health, Castle Biosciences, Delcath Systems, Immatics, Immunocore, Novartis, Pfizer, TriSalus Life Sciences. Travel and accommodations: InxMed, TriSalus Life Sciences.

Dr. Marlana M. Orloff, MD
Associate Professor of Medical Oncology
Alexander & Johnston Family Endowed Clinical Director of Uveal Melanoma
Co-Director Melanoma Research Institute of Excellence
Department of Medical Oncology
Sidney Kimmel Cancer Center
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania

Disclosure of Conflicts of Interest: Dr. Orloff discloses Consulting/Advisory Board: Immunocore, Ideaya, TriSalus, Replimune.

Dr. Shaheer Ahmad Khan, MD
Oncology, Northwell Health
New York, New York

Disclosure: Dr Khan has served as an advisor or consultant to Regeneron, Ideaya Biosciences, Replimune, and Immunocore.

See More